COX-2 Market Growth Could Be Stalled Until Release Of Long-Term Safety Data
Executive Summary
The effect of the Vioxx withdrawal on the non-steroidal anti-inflammatory drug market will likely be determined by long-term studies of marketed products
You may also be interested in...
Vioxx Fallout Still Hangs Heavy Over FDA Advisory Committees
Four years after Merck removed Vioxx from the market, FDA's advisory committee members are still wary of making a similar mistake. At a July 29 Arthritis Advisory Committee meeting for Roche's Actemra (tocilizumab), panel members expressed concern that elevated LDL levels could portend increased risk of CV events
Vioxx Fallout Still Hangs Heavy Over FDA Advisory Committees
Four years after Merck removed Vioxx from the market, FDA's advisory committee members are still wary of making a similar mistake. At a July 29 Arthritis Advisory Committee meeting for Roche's Actemra (tocilizumab), panel members expressed concern that elevated LDL levels could portend increased risk of CV events
Sanofi-Aventis To Begin Long-Term Acomplia Cardio Safety Study By Fall
Sanofi-Aventis will begin conducting a four-to-five year Acomplia (rimonabant) cardiovascular safety study by the fall, the company said